Cancer Drug Parity Act of 2017
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 7, 2017)
Cancer Drug Coverage Act of 2017
This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.What just happenedMar 17, 2017
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 7, 2017
- Mar 17, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 7, 2017IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 7, 2017IntroReferralIntro-H
Introduced in House
- Mar 7, 2017IntroReferral1000
Introduced in House